Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis

Cancer Research

Volumn 61, Issue 23, 2001, Pages 8527-8533

  Uematsu, Kazutsugu ^a   Yoshimura, Akinobu ^a   Gemma, Akihiko ^a   Hosoya, Yoko ^a   Matsuda, Kuniko ^a   Seike, Masahiro ^a   Kurimoto, Futoshi ^a   Takenaka, Kiyoshi ^a   Kudoh, Shoji ^a   Koizumi, Kiyoshi ^a   Tanaka, Shigeo ^a   Mochimaru, Hiroshi ^a   Kunugi, Shinobu ^a   Fukuda, Yuh ^a   Chin, Koei ^b   Jablons, David M ^b  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; GENE PRODUCT; MICROSATELLITE DNA;

ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG FIBROSIS; MAJOR CLINICAL STUDY; METAPLASIA; POLYMERASE CHAIN REACTION; PRECANCER; PRIORITY JOURNAL;

ACID ANHYDRIDE HYDROLASES; CHROMOSOMES, HUMAN, PAIR 3; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; PULMONARY FIBROSIS;

EID: 0035577769     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients
2. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus
3. The biology of lung cancer
4. Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions
5. Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus
6. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma
7. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers
8. Progress in understanding the molecular pathogenesis of human lung cancer
9. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma
10. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer
11. p53 mutation and allelic loss of chromosome 3p, 9p of preneoplastic lesions in patients with non-small cell lung carcinoma
12. Aberrant methylation of p16 (INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis
13. The FHIT gene 3p14.2 is abnormal in lung cancer
14. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer related FHIT cDNA splicing aberrations
15. Loss of FHIT function in lung cancer and preinvasive bronchial lesions
16. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer
17. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers
18. Replacement of Fhit in cancer cells suppresses tumorigenicity
19. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector mediated fragile histidine triad (FHIT) gene overexpression
20. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control
21. The tumor suppressor protein Fhit. A novel interaction with tubulin
22. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease
23. Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck
24. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas
25. Methylation of the 5′ CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas
26. FHIT mutations in human primary gastric cancer
27. The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers
28. The FHIT gene product is highly expressed in the cytoplasm of renal tubular epithelium and is down-regulated in kidney cancers
29. Abnormal Fhit expression in malignant and premalignant lesions of the cervix
30. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines
31. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions
32. The prognosis of cryptogenic fibrosing alveolitis
33. Cryptogenic fibrosing alveolitis and lung cancer
34. Clinical deterioration in patients with idiopathic pulmonary fibrosis: Causes and assessment
35. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study
36. Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections
37. ERBB 2 amplification in breast cancer analyzed by fluorescence in situ hybridization
38. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers
39. 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer
40. Field cancerization in the aerodigestive tract-its etiology, manifestation, and significance
41. K-ras gene point mutation in neogenetic lesions of subpleural fibrotic lesions: Either an early genetic event in lung cancer development or a non-specific genetic change during the inflammatory reparative process
42. Bronchiolization of the alveoli in lung cancer: Pathology, patterns of differentiation and oncogene expression
43. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure
44. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis
45. Cigarette smoking: A risk factor for idiopathic pulmonary fibrosis
46. Association between cigarette smoking and FHIT gene alterations in lung cancer
47. Chromosome 3p14 alterations in lung cancer: Evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos